Repligen
US bioprocessing technology company (RGEN) — XCell ATF alternating tangential flow filtration, KrosFlo TFF systems, Opus pre-packed chromatography columns; leader in single-use perfusion and continuous bioprocessing enabling cell densities >100M cells/mL; strong 2025 recovery after 2023 destocking.
- Country
- United States
- Revenue
- $791M
- Employees
- ~2,000 emp
ISO 9001
FDA GMP
Coverage
| CN | EU | US | |
|---|---|---|---|
| downstream-purification | ✓ | ✓ | ✓ |
Regulatorsfdaema
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Downstream Purification & Bioseparation | downstream-purification | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.